Natera, Inc. $NTRA Stock Holdings Increased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 10.4% during the third quarter, HoldingsChannel.com reports. The firm owned 66,016 shares of the medical research company’s stock after acquiring an additional 6,208 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Natera were worth $10,627,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Rakuten Investment Management Inc. bought a new position in Natera during the third quarter valued at about $34,096,000. SWS Partners raised its stake in shares of Natera by 11.8% in the 3rd quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock valued at $7,572,000 after acquiring an additional 4,980 shares in the last quarter. Vontobel Holding Ltd. lifted its holdings in Natera by 192.5% in the 3rd quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock worth $1,373,000 after purchasing an additional 5,614 shares during the last quarter. Baird Financial Group Inc. boosted its position in Natera by 277.8% during the second quarter. Baird Financial Group Inc. now owns 26,624 shares of the medical research company’s stock worth $4,498,000 after purchasing an additional 19,576 shares during the period. Finally, Orion Porfolio Solutions LLC grew its holdings in Natera by 68.8% during the second quarter. Orion Porfolio Solutions LLC now owns 12,140 shares of the medical research company’s stock valued at $2,051,000 after purchasing an additional 4,946 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced completion of enrollment in the randomized ACES?EMB heart?transplant trial — a clinical milestone for the transplant franchise (Prospera) that de?risks the program’s pathway to clinical readouts and potential uptake. Article Title
• Positive Sentiment: Wall Street coverage remains largely favorable: multiple firms maintain buy/outperform views and several have raised targets (MarketBeat summary shows consensus around a “Moderate Buy” and an average target near $249). This supports upside expectations if results and growth continue.
• Neutral Sentiment: Natera reported preliminary Q4 revenue (details in the alert). Preliminary figures may influence sentiment when the final quarter report and guidance are released; investors should watch the formal Q4 release for confirmation versus consensus. Preliminary Q4 Revenue
• Neutral Sentiment: Institutional ownership remains extremely high (~99.9%), which tends to stabilize the shareholder base but can also concentrate selling/Buying flows when large holders move. (Source: MarketBeat summary.) Institutional Data
• Negative Sentiment: Multiple insider sales by senior executives: CFO Michael Burkes Brophy sold several tranches (totaling 5,064 shares across Jan. 20–29) and CEO Steven Chapman sold several thousand shares (roughly 5,970 shares across Jan. 27–28). These trades total millions of dollars and may create short?term selling pressure despite insiders retaining large residual stakes. CFO Form 4 CEO Form 4
• Negative Sentiment: Other insiders (John Fesko, Solomon Moshkevich) also sold smaller tranches. While each reduction is under ~1% of those insiders’ holdings, the cluster of sales amplifies negative signaling to the market. Fesko Form 4 Moshkevich Form 4

Natera Trading Down 0.1%

Shares of NASDAQ:NTRA opened at $231.14 on Friday. The business’s 50 day moving average is $235.91 and its 200-day moving average is $193.80. The firm has a market capitalization of $31.97 billion, a PE ratio of -100.93 and a beta of 1.62. Natera, Inc. has a 1-year low of $125.38 and a 1-year high of $256.36.

Natera (NASDAQ:NTRA) last issued its earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The firm had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The firm’s revenue for the quarter was up 34.7% compared to the same quarter last year. During the same period last year, the business earned ($0.26) earnings per share. On average, sell-side analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Insider Buying and Selling at Natera

In related news, CEO Steven Leonard Chapman sold 3,648 shares of the stock in a transaction dated Wednesday, January 28th. The shares were sold at an average price of $237.66, for a total value of $866,983.68. Following the completion of the transaction, the chief executive officer owned 213,180 shares of the company’s stock, valued at $50,664,358.80. This represents a 1.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John Fesko sold 928 shares of the firm’s stock in a transaction dated Wednesday, January 28th. The stock was sold at an average price of $237.66, for a total transaction of $220,548.48. Following the transaction, the insider owned 175,540 shares of the company’s stock, valued at approximately $41,718,836.40. This represents a 0.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 514,528 shares of company stock worth $114,975,330. Insiders own 5.63% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on NTRA shares. Guggenheim upped their price objective on shares of Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a report on Monday, January 5th. Stephens upped their price target on shares of Natera from $197.00 to $235.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Citigroup initiated coverage on Natera in a research note on Wednesday, January 7th. They issued a “buy” rating and a $300.00 price objective on the stock. BTIG Research increased their target price on Natera from $230.00 to $260.00 and gave the company a “buy” rating in a research note on Friday, December 5th. Finally, Piper Sandler lifted their price target on Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $249.20.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.